Softbank Group leads the $93mn investment in Petuum Inc

By Catherine Sturman
Softbank has been behind the substantial growth of Petuum Inc, closing $93 million in Series B funding, with participation from previous investorAdvante...

Softbank has been behind the substantial growth of Petuum Inc, closing $93 million in Series B funding, with participation from previous investor Advantech Capital.

Implementing machine learning applications to be deployed at scale, transforming businesses and supporting long-term growth, Petuum’s flexible operating system and virtualisation interface will enable users to build any type of machine learning or deep learning application, which can then be utilised on a wide range of enterprise hardware – including datacentres and IoT – where the management of applications and hardware are then able to come from a single terminal.

"We are firm believers in the value that AI can bring to a broad range of industries," said SoftBank Managing Partner Deep Nishar. "Petuum's work will finally help to unlock that value."

Related stories

One particular area of interest for the company is the digitisation of the healthcare industry and the need for software which can support the ongoing delivery of patient-centric care through the use of advanced data analytics. The use of Electronic Medical Records is becoming an increased area of focus and how such systems can be made more efficient across the board.

With this in mind, tech giants such as Apple and Amazon are continuing to look at the long-term growth of the healthcare industry and use of AI, alongside the growing use of health wearables and use of VR through the delivery of personalised care. This is also in alignment with a growing consumer healthcare market.

Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19